-- Redhill Jumps Most in Month After FDA Approves Drug Trial
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-02-12T10:38:52Z
-- http://www.bloomberg.com/news/2012-02-12/redhill-jumps-most-in-month-after-fda-approves-drug-trial.html
Redhill Biopharma Ltd. (RDHL)  surged the
most in more than a month after the Israeli biopharmaceutical
company said it received U.S. Food and Drug Administration
approval for a clinical trial of its RHB-102 drug.  The  shares  jumped 8.3 percent, the most since Jan. 3 in
intraday trading, to 2.32 shekels at 12:19 p.m. in  Tel Aviv ,
giving the company a market value of 120 million shekels ($32
million).  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  